Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01545466
Other study ID # 2011P001654
Secondary ID
Status Completed
Phase N/A
First received February 24, 2012
Last updated March 11, 2013
Start date February 2012
Est. completion date October 2012

Study information

Verified date March 2013
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This proposal describes a randomized controlled pilot trial investigating feasibility, safety, and migraine frequency in patients with migraines who undergo an 8 week mindfulness based stress reduction (MBSR) program compared to a wait-list control group.


Description:

Preliminary research has shown MBSR to be effective in chronic pain syndromes and other mind/body interventions have shown good promise in the treatment of headaches. A randomized controlled trial (RCT) of yoga in migraine without aura patients by John and colleagues showed that yoga resulted in a significant decrease in headache frequency, pain index, and symptomatic medication usage compared to a self-care group. This RCT demonstrated that patients with headaches may benefit from a mind-body intervention. However, their yoga protocol was not specified, and participants were instructed to practice the technique only during the prodromal phase of a headache (prior to the pain becoming severe), so as an abortive intervention at the time of a headache. Thus, the investigators of this trial are proposing to evaluate the effect of MBSR on adults with migraines compared to an education control group. This study will add to the John study because, unlike many other mind-body interventions, MBSR offers the distinct advantage of a standardized protocol that has been used both clinically and in numerous research studies across a wide variety of conditions. Furthermore, MBSR teaches participants a daily practice that, if effective, could serve as a prophylactic intervention.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of migraine (International Classification of Headache Disorders-II);21

- 4-14 days with migraines/month

- =one year of migraines

- =18 years

- Able and willing to attend weekly sessions and willing to participate in daily mindfulness assignments, up to 30-45 min/day

- Agreeable to participate and to be randomized to either group

- Fluent in English (since the treatment groups will be run in English)

- Good general health with no additional diseases expected to interfere with the study

Exclusion Criteria:

- Current regular meditation/yoga practice

- Any major systemic illness or unstable medical or psychiatric condition (e.g. suicide risk) requiring immediate treatment or that could lead to difficulty complying with the protocol

- Diagnosis of medication overuse headache (International Classification of Headache Disorders-II);19

- Current or planned pregnancy or breastfeeding

- New prophylactic migraine medicine started within 4 weeks of the screening visit

- Unwilling to maintain stable current doses of migraine medicines for the duration of trial

- Failure to complete baseline diary recordings of migraine activity and medication use

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness Based Stress Reduction (MBSR)
MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Migraine frequency from Baseline Change in the number of migraines per month from baseline(tracked with headache logs) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in self-efficacy from baseline Change in self-efficacy from baseline(Headache Management Self-Efficacy Scale) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in perceived stress from baseline Change in Perceived stress scale from baseline baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in migraine-related disability/impact from baseline Change in migraine-related disability/impact from baseline(one month MIDAS and HIT-6) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in anxiety from baseline Change in anxiety from baseline (state-trait anxiety measure) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in depression from baseline Change in depression from baseline(PHQ-9) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in mindfulness from baseline Change in mindfulness from baseline(Five facet mindfulness scale) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Qualitative interviews Participants will be interviewed qualitatively immediately post-intervention
Secondary Change in migraine severity from baseline Change in Migraine intensity (1-10) tracked via headache logs from baseline baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in Migraine duration from baseline Length of migraines (tracked via headache logs) baseline, immediately post-intervention, 4 weeks post-intervention
Secondary Change in quality of life from baseline Change in Migraine specific quality of life from baseline baseline, immediately post-intervention, 4 weeks post-intervention
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A